RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Medicenna Therapeutics Stock

Medicenna Therapeutics Employees 2025

Medicenna Therapeutics Employees

7

Ticker

MDNA.TO

ISIN

CA58490H1073

In 2025, Medicenna Therapeutics employed 7 people, a 0% change from the 7 number of employees in the previous year.

Medicenna Therapeutics Aktienanalyse

What does Medicenna Therapeutics do?

Medicenna Therapeutics Corp is a biopharmaceutical company based in Canada that specializes in the development of treatments for serious diseases such as cancer or neurodegenerative disorders. The company was founded in 2011 and went public in 2019. Medicenna's business model is based on the use of state-of-the-art technologies and innovative approaches to disease treatment. This includes the use of immunotherapies that specifically strengthen the patient's own immune system to help fight diseases. Medicenna is divided into several divisions, each with different focuses. The first division is the development of treatments for brain tumors such as glioblastomas, which can occur in adults and children. The company has developed a unique technology called "Superkines" that enables it to manipulate the patient's immune system to attack and destroy brain tumors. This technology has already been tested in clinical trials with promising results. Another division of Medicenna specializes in the treatment of severe cancers such as lung cancer or triple-negative breast cancer. The company uses both immunotherapies and targeted therapies to inhibit the growth of cancer cells and strengthen the patient's own immune system. In addition to drug development, Medicenna also offers consulting services to support other companies in the development of therapies. This includes identifying potential target molecules and optimizing drug candidates. Overall, Medicenna has several promising products in its pipeline, currently in different phases of clinical development. The most advanced product is MDNA55, a superkine for the treatment of glioblastoma, which is already in clinical phase III trials. Other promising products include MDNA19, a targeted immunotherapy for the treatment of lung cancer, and MDNA57, a therapy for triple-negative breast cancer. All in all, Medicenna has established itself as one of the most promising biotech companies in the market. With its innovative therapy approaches and promising products, the company is well positioned to make a sustainable impact on the field of biomedicine and help patients fight serious diseases. Medicenna Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Medicenna Therapeutics's Employee Base

Medicenna Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Medicenna Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Medicenna Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Medicenna Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Medicenna Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Medicenna Therapeutics stock

How many employees does Medicenna Therapeutics have this year?

Medicenna Therapeutics has 7 undefined employees this year.

How many employees did Medicenna Therapeutics have compared to the previous year?

Compared to the previous year, Medicenna Therapeutics had 0% more employees.

What impact did the number of employees have on the company Medicenna Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Medicenna Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Medicenna Therapeutics?

The number of employees can also have an impact on investors of Medicenna Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Medicenna Therapeutics affect the company?

An increase in equity of Medicenna Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Medicenna Therapeutics's equity affect the company?

A reduction in equity of Medicenna Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Medicenna Therapeutics?

Some factors that can influence the equity of Medicenna Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Medicenna Therapeutics so important for investors?

The equity of Medicenna Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Medicenna Therapeutics influence the company?

The number of employees at Medicenna Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Medicenna Therapeutics evolved in recent years?

In recent years, the number of employees at Medicenna Therapeutics has changed by 0.

How many employees does Medicenna Therapeutics currently have?

Medicenna Therapeutics currently has 7 undefined employees.

Why is the number of employees important for investors of Medicenna Therapeutics?

The number of employees is important for investors of Medicenna Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Medicenna Therapeutics take to change the number of employees?

To change the number of employees, Medicenna Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Medicenna Therapeutics pay?

Over the past 12 months, Medicenna Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medicenna Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Medicenna Therapeutics?

The current dividend yield of Medicenna Therapeutics is .

When does Medicenna Therapeutics pay dividends?

Medicenna Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Medicenna Therapeutics?

Medicenna Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Medicenna Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Medicenna Therapeutics located?

Medicenna Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Medicenna Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Medicenna Therapeutics from 8/16/2025 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 8/16/2025.

When did Medicenna Therapeutics pay the last dividend?

The last dividend was paid out on 8/16/2025.

What was the dividend of Medicenna Therapeutics in the year 2024?

In the year 2024, Medicenna Therapeutics distributed 0 CAD as dividends.

In which currency does Medicenna Therapeutics pay out the dividend?

The dividends of Medicenna Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Medicenna Therapeutics

Our stock analysis for Medicenna Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medicenna Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.